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1. Introduction 
The common aetiologies of gangrene of the extremities are atherosclerosis and diabetes 
mellitus. An internist may encounter several other diseases which can cause gangrene of 
extremities. Systemic lupus erythematosus, progressive systemic sclerosis, Henoch-
Schonlein  purpura,  anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 
Takayasu  arteriitis, infective endocarditis, gangrene associated with procoagulant states 
due to malignancy, anticardiolipin antibody syndrome and disseminated intravascular 
coagulation are some of the important causes of  gangrene of the extremities. Rare causes of 
gangrene include heparin induced thrombocytopenia (HIT), haemolytic uremic syndrome 
(HUS) and Human immunodeficiency virus (HIV) infection. 
HIV infection involves all the systems of the body, and the cardiovascular system is no 
exception. HIV vasculopathy was first described as an entity in 1987 (Joshi et al., 1987). HIV 
associated vasculopathy may present with arterial occlusive disease, aneurysmal disease, 
aortic dissection or spontaneous arteriovenous fistula (Mulaudzi, 2005; Nair, 1999, 2000, 
2001; Pantula, 2009). Vasculitis is one of the less common but important consequences of 
HIV (Chetty, 2001). Aneursymal disease is thought to be due to vasculitis of vasa vasorum 
leading to inflammation with resultant transmural fibrosis or necrosis and the formation of 
true or false aneurysms (Mulauldzi et al., 2005).  HIV-related thrombosis, which is 
segmental, shows a histological picture identical to that seen in aneurysms, with 
inflammatory changes confined to the vasa vasora with bland organising luminal 
thrombosis. This strongly suggests that aneurysm and thrombosis are different expressions 
of the same pathological process. 
Peripheral arterial disease (PAD) is more prevalent in the HIV-infected population than in 
the general population (Periard, 2008).  There is a six-fold increased risk for PAD in HIV-
infected individuals as well as an earlier onset of the disease compared with HIV-negative 
patients (Periard et al., 2008). Broad spectrum of rheumatic syndromes are associated with 
HIV infection ranging from arthralgias to reactive arthritis, myopathy and fibromyalgia to 
more severe necrotizing vasculitis (Uppal & Achutan, 1997). Almost every pattern and type 
of vasculitis of small, medium and large vessels has been encountered in the HIV setting 
(Chetty, 2001). Widespread digital ischemic changes and gangrene of the hands and feet is 
an uncommon presentation in patients with HIV infection (Roh & Gertner, 1997). There are 
several reports on HIV associated occlusive vasculopathy from Africa. Reports from India 
on this subject are limited.  
www.intechopen.com
 
Gangrene – Current Concepts and Management Options 106 
2. Materials and methods 
Data of 1311 HIV reactive patients was obtained retrospectively from the medical records of 
department of medicine from the year 2000 to 2010. All HIV positive patients’ records were 
studied. Records of patients with gangrene were identified and studied.  
HIV testing was done by HIV Vironostika (4th Generation ELISA, BioMerieux, France). All 
HIV reactive samples were then tested by HIV TRIDOT (J Mitra, India), a rapid assay that 
allows differentiation between HIV 1 and 2. The reactive samples were further confirmed by 
a Western Blot assay (HIV Blot 2.2, Gene labs Diagnostics, USA). CD4 counts were 
determined by using the FACS Count (Becton Dickinson, USA). HIV Viral loads were 
estimated by the AMPLICOR assay (Roche, USA). 
3. Our experience 
In our experience over the last 10 years in a south Indian tertiary care hospital we have seen 
only 2 cases of HIV associated gangrene out of the 1311 cases HIV infected patients. We 
describe our experience of one of our patients of HIV infection with gangrene. 
3.1 Case report 
A woman aged 32 years presented to the outpatient department of our institute with 
complaints of pain and blackish discoloration of left foot since 1 month. She did not have 
diabetes mellitus or hypertension. She was non smoker and non alcoholic. There was no 
history of coronary artery disease or cerebrovascular diseases. 
On examination she was emaciated. Pallor and oral thrush were noted. There was no 
lymphadenopathy. Vitals were normal. Cardiovascular, abdomen and respiratory systems 
were normal. Left foot was dry, gangrenous with blackish discoloration (Figure 2). Dorsalis 
pedis, posterior tibial pulses were not palpable. Sensations decreased on the foot. 
Hemoglobin was 10 gm/dL, Total leucocyte count was 10,000/cmm with neutrophils 66%, 
lymphocytes 28%, Eosinophils 4%, and monocytes 2%. Platelets were normal. Peripheral 
smear examination showed normocytic, normochromic anemia.   Erythrocyte sedimentation 
rate was 20mm at 1st hour. Liver function tests and renal function tests were normal. Lipid 
profile was normal. Anti nuclear factor (ANF), perinuclear and cytoplasmic anti neutrophil 
cytoplasmic antibodies (P and C-ANCA) were negative. Australian Antigen and HCV 
antibodies were negative.  
She was evaluated and was found to have HIV-1 infection. CD4 count was 106 cells/µL. 
Patient’s spouse was tested reactive for HIV 1 and was receiving HAART. She had one male 
child who was 8 years old and had been tested non reactive for HIV infection. She was 
started on highly active antiretroviral therapy (HAART) and low dose prednisolone. Pain 
reduced and a line of demarcation developed.  
4. Discussion 
HIV-associated vascular disease is a specific disease entity which differs from 
atherosclerotic disease in various aspects. HIV positive patients with vasculopathy are 
younger with an average age of 40 years in comparison to 55 years in patients with 
atherosclerotic disease (Botes & Van Marle, 2007). There is also a lower incidence of the 
typical risk factors for atherosclerosis like smoking, hypertension, hypercholesterolemia and 
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Fig. 1. Gangrene involving left foot in a woman aged 32 years with HIV infection 
count < 200 cells/μl was found as significant predictor of PAD in HIV (Periard et al., 2008). 
Literature suggests that the incidence of symptomatic vasculitis is in the region of 0.4% to 
1% of HIV-infected patients (Kaye, 1996; Kakrani et al., 2003). However, we have seen only 2 
cases of HIV associated gangrene over last 10 years. The reason for the low incidence in our 
experience is possibly due to the free antiretroviral treatment (ART) at the government 
funded ART centres in our state. Another reason for the low incidence of peripheral 
vascular disease is because we did not screen for any subclinical vascular disease in our 
patients.  As observed in our cases CD4 counts in patients with HIV vasculopathy are below 
normal in more than 90% of patients and the CD4:CD8 ratio is usually reversed, indicative 
of advanced immunosuppression (Mulaudzi et al., 2005). 
4.1 Etiology of gangrene in HIV 
Infections, occlusive disease due to a hypercoagulable state, vasculitis are some of the 
mechanisms suggested for gangrene of the extremities in HIV. There have been reported 
findings of anti-phospholipid antibody syndrome, deficiencies of free protein S, protein C 
and anti-thrombin 3, but these have been sporadic reports. Chronic HIV infection, rather 
than its pharmacologic treatment, induces alterations of markers of endothelial dysfunction 
(Torriani et al 2008). However some opine that despite minimizing HIV plasma burden and 
subsequent associated inflammatory damage, antiretroviral medications may independently 
contribute to endothelial damage (Gaetano et al., 2003; Chai et al., 2005; Shankar et al., 2005). 
www.intechopen.com
 
Gangrene – Current Concepts and Management Options 108 
HIV-infected patients tend to develop decreases in high density lipoprotein cholesterol 
(HDL-c) and low density lipoprotein cholesterol (LDL-c) levels, followed by an increase in 
plasma triglyceride levels, independent of any exposure to antiretroviral therapy (Grunfeld 
et al., 1992).  
Viral infections have been implicated in the pathogenesis of systemic vasculitis, and many 
viruses, including HIV, are associated with vasculitis and occasionally gangrene. As in any 
immunocompromised state, opportunistic infections are likely in patients with HIV 
infection.  Vasculitis and gangrene may be a manifestation of these opportunistic infections.   
Cytomegalovirus (CMV), Herpes zoster virus (HZV), toxoplasmosis, pneumocystis, 
salmonella, and Mycobacterium tuberculosis have all been associated with vasculitis in 
patients with HIV infection1. The two major mechanisms by which infection is thought to 
induce a vasculitis are direct microbial invasion, with resultant damage of the vessel wall, 
and immune mediated injury both humoral and cellular (Chetty, 2001).  
Another mechanism for development of vasculitis in patients after start of antiretroviral 
therapy (ART) is immune-reconstitution inflammatory syndrome (IRIS). IRIS occurs within 
a few weeks to months after the start of HAART; patients most often present with clinical 
deterioration while the number of CD4 lymphocytes is increasing and the HIV viral load 
decreasing. IRIS could be implicated in the pathogenesis of the vascular complications 
(Venkataramana et al., 2006).  
Various abnormalities predisposing to a hypercoagulable state have been detected in HIV 
patients, including antiphospholipid antibodies, lupus anticoagulant, increased Von 
Willebrand factor (vWF), deficiency in protein C and S, antithrombin and heparin co-factor. 
Viral-induced endothelial injury causes increased levels of Von Willebrand factor, total 
antigenic protein S, plasminogen activator inhibitor (PAI-1), endothelial-derived 
thrombomodulin and other procoagulant products of endothelial cell activation (Saif et al., 
2001). Some of the rare causes which contribute to gangrene in HIV include thrombotic 
thrombocytopenic purpura (de Man et al., 1997).  
4.2 Clinical features 
HIV-associated arterial occlusive disease is recognised as a specific clinical entity. Median 
age of patients is between 30 - 40 years (Mulaudzi et al., 2005). Male preponderance has been 
observed in HIV associated vasculopathy (Mulaudzi et al., 2005). The vessels reported to be 
commonly affected are arteries of muscles and digits. In HIV related occlusive vascular 
disease two patterns of presentation have been reported (Robbs & Paruk, 2010). In the first 
type, there is no antecedent claudication and patients present with acute thrombosis. In this 
type angiographically, proximal vessels appear normal but there is segmental occlusion 
with poor distal runoff. The second group with occlusive disease appears to have premature 
atherosclerotic disease. The majority of the patients present with critical ischaemia with rest 
pain or gangrene. 
In most patients the disease is confined to one limb, for reasons that are obscure. However 
there are case reports describing gangrene involving upper limbs in children with HIV 
(Despina et al., 2008). Cases of polyarteritis nodosa (PAN) like systemic necrotizing 
vasculitis in HIV infected individuals, with digital ischaemia are reported (Kakrani et al., 
2003).   As vasculopathies occur during the later stages of the HIV disease process and are a 
marker for advanced disease, a thorough search for opportunistic infections should be made 
in these patients. There are reports of increase in prevalence of Fournier’s gangrene in 
patients with HIV in their surgical ward during post HIV era (Elem& Ranjan, 1995).  There 
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are case reports from India on gangrene involving unusual sites like breast in HIV patients 
(Venkatramani et al., 2009.) 
4.3 Diagnosis 
HIV associated gangrene may be associated with a known pathogen or trigger, or may occur 
in the absence of an obvious identifiable agent. To establish an opportunistic infection 
associated with the vascular pathology either a serological test, staining of smears on light 
microscopy, cultures,  immunohistochemistry testing , and in situ hybridisation tests or viral 
markers may be done as are relevant based on the clinical presentation. 
Work up for autoimmune diseases and procoagulant states- antinuclear antibodies, 
antiphospholipd antibodies, protein C, S and anti- thrombin III need to be planned in 
patients with HIV with gangrene. Patients with peripheral arterial disease can be easily and 
reliably identified by ankle brachial index (ABI) testing, and they presumably are at 
increased cardiovascular risk, assuming that ABI mortality correlations from the general 
population can be extrapolated to HIV-infected persons (Periard et al., 2008).  
Doppler study of arterial and venous system is essential in all patients with ischemic 
changes. There is a pathognomonic sign with hypoechoic spotting within the arterial wall 
best described as string of pearls sign (Woolgar et al., 2002). 
Diagnostic angiography in known HIV-positive patients with vasculopathy requires 
awareness of the manifestations of the disease (Scholtz, 2004). The uncommon sites and 
multiplicity of vascular involvement usually imply that additional images, with an 
increased volume of contrast media, will be required. Owing to the increased risk of 
thrombosis, care should be taken to adequately heparinize these patients during diagnostic 
or interventional procedures. In a series on vascular involvement in HIV patients, it was 
noted that the majority of the patients presented with occlusive disease, followed by 
aneurysms, usually atypical in location, multiple, clustered and with a  predilection for the 
extracranial carotid arteries followed by the thoracoabdominal aorta and superficial femoral 
arteries(Sholtz, 2004). Angiographic appearances vary in the two types of HIV related 
occlusive vascular disease. In the acute thrombosis group, the angiographic picture is one in 
which the proximal vessels are normal, accompanied by aggressive peripheral thrombotic 
occlusion and very poor distal runoff. 
A careful clinicopathological correlation is particularly important in skin biopsies showing a 
vasculitic reaction. There are five patterns of vasculitis described in HIV i.e. lymphocytic 
vasculitis(LyV), leucocytoclastic vasculitis(LCV) of small dermal vessels, neutrophilic 
vasculitis with vascular thrombosis and intradermal suppuration, vasculitis with palisaded 
neutrophilic neutrophilic and granulomatous dermatitis and large vessel vasculitis affecting 
subcutaneous vessels (Grayson, 2008). 
The last three patterns usually infer systemic involvement. A neutrophilic (leucocytoclastic) 
vasculopathic reaction in the HIV positive individual may have many potential causes, 
including infection with HIV per se. Other viral causes of hypersensitivity vasculitis include 
CMV, hepatitis B virus, and Epstein–Barr virus. The dermal vessels in skin biopsies from cases 
of HSV or varicella zoster virus (VZV) infection frequently exhibit LCV. Recurrent varicella 
may even manifest with vasculitis in the absence of epidermal involvement.  Drugs that may 
precipitate LCV include certain HAART agents, penicillin and the sulphonamides. The 
presence of acute LCV in association with vascular occlusion may signify either HIV-
associated mixed cryoglobulinaemia (with small vessel occlusion by cryoglobulin precipitates) 
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or septic vasculitis (with dermal vascular occlusion by infected microthrombi). The latter may 
be associated with intradermal abscess formation and/or cutaneous infarction (Carlson, 2005).  
4.4 Management 
HIV-associated vasculopathy is not cited in the World Health Organization (WHO) clinical 
staging system. As HIV associated vasculopathy and gangrene are pointers to an advanced 
stage of the disease it would be logical to offer antiretroviral therapy irrespective of the CD4 
level. Recent publications have shown that HIV itself as a risk factor for peripheral artery 
disease and strongly recommended NRTI and NNRTI containing regimens (Ye, 2010). As a 
class, the protease inhibitors appear to have the greatest negative impact on total cholesterol 
and triglyceride levels; however, even within this class, certain agents e.g., atazanivir and 
darunavir do not have an adverse effect on lipids. 
The treatment in patients with acute thrombosis type of occlusive disease depends on the 
clinical presentation. In those patients wherein the limb cannot be salvaged primary 
amputation is done. Where the limb is salvageable treatment options include endovascular 
procedures like thrombectomy and thrombolysis or bypass procedures. However, the limb 
salvage rate has been in the region of 27% (Mulaudzi et al., 2005). This is thought to be due 
to the fact that it is mainly a vasculitic process with superimposed thrombosis, and 
removing the thrombus does not, in effect, solve the problem, which has a very high re-
thrombosis rate3.  
Patients with HIV infection with widespread ischemic necrosis and gangrene may require 
treatment with corticosteroids (in the event of possible vasculitis), thrombolytic agents (for 
the thrombotic component), or both, unless there are contraindications to either (Roh & 
Gertner, 1997).  
In those with chronic occlusive type of disease, in almost half of the patients, there may not 
be a possibility of reconstruction due to poor runoff or the limb may be beyond salvage. In 
others standard bypass procedures can be performed and only recently have endovascular 
procedures been attempted. In this group, the results are marginally better than in the 
patients with acute thrombosis type of occlusive disease. (Robbs & Paruk, 2010). 
Patients should be optimized as per standard practice prior to surgical or endovascular 
intervention. Vascular surgical principles should be adhered to when managing patients 
with HIV-associated occlusive vasculopathy and management should be individualized. 
Various authors have identified a CD4 T-cell count of less than 200 cells/μl is an important 
risk factor for postoperative complications (Lin et al., 2004; Albaran, et al., 1998). A 
significant complication in all patients in whom surgery is attempted has been the high rate 
of superficial wound sepsis and graft sepsis. Some centers with vast experience with 
surgical procedures for occlusive vascular disease in HIV have reported a perioperative 
mortality of 6.95% (Van Marle et al., 2009). Primary amputation is usually done for very 
advanced arterial disease. 
5. Conclusions 
One of the unforeseen consequences of untreated long standing infection with HIV is the 
appearance of various rheumatic syndromes. Clinicians encountering a patient with 
gangrene should consider HIV as an important cause and screen for presence of HIV 
antibodies. Early detection of the HIV infection and appropriate and timely start of HAART 
can possibly prevent vascular complications.  In every patient, workup for both traditional 
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and specific risk factors including opportunistic infections and prothrombotic states should 
be done. Appropriate treatment for the ischemic limb as well as treatment of opportunistic 
infections and HAART when indicated may significantly improve the outcomes. Screening 
for subclinical vascular disease in asymptomatic patients with simple measures like ankle 
brachial index and appropriate timely treatment will go a long way in preventing the 
development of gangrene.  
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